Phase1/2 study of Nabpaclitaxel,Gemcitabine,S1 combination therapy for unresectable pancreatic cancer
Not Applicable
Recruiting
- Conditions
- unresectable pancreatic cancer
- Registration Number
- JPRN-UMIN000030007
- Lead Sponsor
- Kobe University Hospital Department of Hematology and Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1.Interstitial pneumonitis or pulmonary fibrosis 2.uncontorolled diabetes, liver failure, angina pectoris,myocardial infarction within 3 months after the onset 3.severe infection 4.pregnant woman,lactation,possibility or intention of pregnancy 5.serious drug allergy 6.psychiatric symptoms or mental illness 7.Moderate or severe ascites, pleural effusion 8.uncontrolled watery diarrhea 9.unsuitable for safely carrying out this trial 10.double cancer affected performance status
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase 1 part: determination of maximum tolerated dose and recommended dose Phase 2 part: response rate
- Secondary Outcome Measures
Name Time Method